Has Sadeer Hannush, MD received payments from drug or device companies?

Yes. Drug and device makers reported $32,645 in general payments to Sadeer Hannush, MD across 44 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sadeer Hannush, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sadeer Hannush, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sadeer Hannush, MD

Ophthalmology · Langhorne, PANPI 1780637942

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,100 of the $32,645 with a category attached, or 89.1%. Kowa Research Institute, Inc. accounts for 89.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $22,069 and has fallen 92.5% since, to $1,661 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,645in general payments, 2019–2025

Across 44 payments — averaging $741.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kowa Research Institute, Inc.$29K
Kowa Pharmaceuticals America, Inc.$1K
Biotissue Holdings Inc.$344
Sight Sciences, Inc.$261
Alcon$245
Rxsight Inc$234
plus $994 from 12 others

What the payments were for

Consulting fees$29,10089%
Speaking & faculty fees$1,4674%
Travel & lodging$1951%
Food & beverage$1,8846%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kowa Research Institute, Inc.	5	$29,100
Kowa Pharmaceuticals America, Inc.	1	$1,467
Biotissue Holdings Inc.	3	$344
Sight Sciences, Inc.	2	$261
Alcon	4	$245
Rxsight Inc	2	$234
Abbott	10	$216
KOWA Company, LTD.	2	$211
Carl Zeiss Meditec, Inc.	1	$106
Johnson & Johnson Surgical Vision, Inc.	1	$79
Eyepoint US, Inc.	1	$78
Dompe US, Inc.	2	$71
Genentech USA, Inc.	3	$70
Thea Pharma Inc.	3	$60
Carl Zeiss Meditec USA, Inc.	1	$43
Tarsus Pharmaceuticals, Inc.	1	$30
Apellis Pharmaceuticals, Inc.	1	$16
Bausch & Lomb Americas Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OMNI(R) SURGICAL SYSTEM (US)$261
RXSIGHT CONTACT LENS$156
RXSIGHT INJECTOR CARTRIDGE$156
RXSIGHT INJECTOR HANDPIECE$156
RXSIGHT LIGHT DELIVERY DEVICE (LDD)$156
RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$156
Clareon$129
Prokera$121
AmnioGraft$121

How this compares

$32,645 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$199,607

Medicare patients

347

Services billed

1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Loteprednol Etabonate	219	$37,646
InveltysLoteprednol Etabonate	28	$15,719
Lotemax SmLoteprednol Etabonate	53	$13,142
Prednisolone Acetate	270	$12,953
Fluorometholone	130	$12,444
ProlensaBromfenac Sodium	32	$11,013
FlarexFluorometholone Acetate	81	$10,281
TobradexTobramycin/Dexamethasone	18	$6,323
BesivanceBesifloxacin Hcl	19	$4,602
MoxifloxacinMoxifloxacin Hcl	217	$3,404
ValacyclovirValacyclovir Hcl	31	$1,895
Timolol Maleate	94	$642
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate	39	$602
ErythromycinErythromycin Base	59	$580
Acyclovir	14	$446

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Langhorne

Julia HallerPhiladelphia$1.5M
Francis MahPittsburgh$1.1M
Brandon AyresBala Cynwyd$929K
David AlmeidaErie$734K
Carl RegilloPlymouth Meeting$721K
Robert NoeckerPittsburgh$632K
Beeran MeghparaPhiladelphia$496K
Michael KlufasPlymouth Meeting$393K
Jonathan MyersPhiladelphia$359K
Mark BlecherPhiladelphia$357K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →